![NCTN group chairs: Cancer trials take backseat to clinical care amid COVID-19 pandemic](https://cdn.cancerletter.com/media/2020/04/21101447/coronavirus_4x3.jpg)
![NCTN group chairs: Cancer trials take backseat to clinical care amid COVID-19 pandemic](https://cdn.cancerletter.com/media/2020/04/21101447/coronavirus_4x3.jpg)
Cover Story
COVID-19 & CancerFreeGuest Editorial
By Charles D. Blanke, Douglas S. Hawkins, Monica M. Bertagnolli, Peter J. O'Dwyer, Mitchell D. Schnall, Walter J. Curran, Norman Wolmark, Robert S. Mannel and Janet Dancey
While the National Clinical Trials Network (NCTN) groups remain open for business during the pandemic, it’s not business as usual. For good reason, clinical trials are taking a backseat to clinical care. Leadership and members themselves face significant challenges treating oncology patients, as attention and resources are diverted to minister to those with COVID-19.
COVID-19 Updates
![COVID-19 Updates](https://cdn.cancerletter.com/media/2021/05/04080942/covid-doodle.jpg)
![COVID-19 Updates](https://cdn.cancerletter.com/media/2021/05/04080942/covid-doodle.jpg)
In Brief
Funding Opportunities
Clinical Roundup
Drugs & Targets
Trending Stories
- When tobacco companies sponsored the Olympics
- Kamala Harris widely expected to continue Cancer Moonshot; Conservatives present their vision in Project 2025
- How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission
- ODAC vote will likely lead to three-arm and four-arm designs–and pragmatic trials–for perioperative indications
- Jonathan Gerber named chief clinical officer of NYU Langone Health’s Perlmutter Cancer Center
- U.S. News rankings for cancer hospitals shift again with inclusion of Medicare Advantage data
Rankings now include a list of Best Regional Hospitals for Equitable Access